Published in Commun Dis Intell Q Rep on January 01, 2005
Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev (2014) 2.45
Evaluation of six commercial nucleic acid amplification tests for detection of Neisseria gonorrhoeae and other Neisseria species. J Clin Microbiol (2011) 1.55
A fast real-time polymerase chain reaction method for sensitive and specific detection of the Neisseria gonorrhoeae porA pseudogene. J Mol Diagn (2006) 1.20
Analytical evaluation of GeneXpert CT/NG, the first genetic point-of-care assay for simultaneous detection of Neisseria gonorrhoeae and Chlamydia trachomatis. J Clin Microbiol (2013) 1.15
Trends in chlamydia and gonorrhea positivity among heterosexual men and men who have sex with men attending a large urban sexual health service in Australia, 2002-2009. BMC Infect Dis (2011) 0.92
Comparison of the cobas 4800 CT/NG test with culture for detecting Neisseria gonorrhoeae in genital and nongenital specimens in a low-prevalence population in New Zealand. J Clin Microbiol (2013) 0.88
Neisseria gonorrhoeae false-positive result obtained from a pharyngeal swab by using the Roche cobas 4800 CT/NG assay in New Zealand in 2012. J Clin Microbiol (2013) 0.87
The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review. Syst Rev (2014) 0.87
Molecular detection and confirmation of Neisseria gonorrhoeae in urogenital and extragenital specimens using the Abbott CT/NG RealTime assay and an in-house assay targeting the porA pseudogene. Eur J Clin Microbiol Infect Dis (2010) 0.85
A randomised trial of point-of-care tests for chlamydia and gonorrhoea infections in remote Aboriginal communities: Test, Treat ANd GO- the "TTANGO" trial protocol. BMC Infect Dis (2013) 0.82
Laboratory results that should be ignored. MedGenMed (2006) 0.78
Supplemental testing is still required in australia for samples positive for Neisseria gonorrhoeae by nucleic acid detection tests. J Clin Microbiol (2006) 0.78
Evaluation of the New BD Max GC Real-Time PCR Assay, Analytically and Clinically as a Supplementary Test for the BD ProbeTec GC Qx Amplified DNA Assay, for Molecular Detection of Neisseria gonorrhoeae. J Clin Microbiol (2015) 0.75
Pharyngeal Gonorrhoea in Women: An Important Reservoir for Increasing Neisseria gonorrhoea Prevalence in Urban Australian Heterosexuals? J Sex Transm Dis (2013) 0.75
Nucleic acid amplification tests (NAATs) for gonorrhoea diagnosis in women: experience of a tertiary care hospital in north India. Indian J Med Res (2014) 0.75
Recorded gonorrhoea rates in Denmark, 1900-2010: the impact of clinical testing activity and laboratory diagnostic procedures. BMJ Open (2015) 0.75
Characterization of a novicida-like subspecies of Francisella tularensis isolated in Australia. J Med Microbiol (2003) 1.97
Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob Agents Chemother (2007) 1.90
Indirect hemagglutination assay in patients with melioidosis in northern Australia. Am J Trop Med Hyg (2006) 1.82
Nucleic acid amplification testing for Neisseria gonorrhoeae: an ongoing challenge. J Mol Diagn (2006) 1.70
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother (2008) 1.36
Epidemiology of community-acquired and nosocomial bloodstream infections in tropical Australia: a 12-month prospective study. Trop Med Int Health (2004) 1.24
Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains. J Antimicrob Chemother (2010) 1.20
The antimicrobial resistance containment and surveillance approach--a public health tool. Bull World Health Organ (2005) 1.17
Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-binding protein 2. J Antimicrob Chemother (2010) 1.16
Studies of measles viruses circulating in Australia between 1999 and 2001 reveals a new genotype. Virus Res (2003) 1.05
Dynamics of appearance and expansion of a prolyliminopeptidase- negative subtype among Neisseria gonorrhoeae isolates collected in Sydney, Australia, from 2002 to 2005. J Clin Microbiol (2006) 1.04
Enhancing gonococcal antimicrobial resistance surveillance: a real-time PCR assay for detection of penicillinase-producing Neisseria gonorrhoeae by use of noncultured clinical samples. J Clin Microbiol (2010) 1.03
Further questions regarding the role of mosaic penA sequences in conferring reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae. Antimicrob Agents Chemother (2006) 1.01
Exploring 'best practice' for nucleic acid detection of Neisseria gonorrhoeae. Sex Health (2008) 1.00
In vitro assessment of the further potential for development of fluoroquinolone resistance in Neisseria meningitidis. Antimicrob Agents Chemother (2005) 0.99
In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea? Antimicrob Agents Chemother (2012) 0.98
Late-onset and recurrent neonatal Group B streptococcal disease associated with breast-milk transmission. Pediatr Dev Pathol (2003) 0.96
Epidemiological characteristics and molecular basis of fluoroquinolone-resistant Neisseria gonorrhoeae strains isolated in Korea and nearby countries. J Antimicrob Chemother (2004) 0.96
Evidence that the gonococcal porA pseudogene is present in a broad range of Neisseria gonorrhoeae strains; suitability as a diagnostic target. Pathology (2006) 0.94
Neisseria gonorrhoeae multi-antigen sequence typing using non-cultured clinical specimens. Sex Transm Infect (2009) 0.94
What management is there for gonorrhea in the postquinolone era? Sex Transm Dis (2006) 0.91
Further evaluation of a rapid diagnostic test for melioidosis in an area of endemicity. J Clin Microbiol (2004) 0.90
Chloramphenicol-resistant Neisseria meningitidis containing catP isolated in Australia. J Antimicrob Chemother (2003) 0.86
Quinolone resistance in Neisseria gonorrhoeae: rapid genotyping of quinolone resistance-determining regions in gyrA and parC genes by melting curve analysis predicts susceptibility. Antimicrob Agents Chemother (2009) 0.86
Simple, rapid, and inexpensive detection of Neisseria gonorrhoeae resistance mechanisms using heat-denatured isolates and SYBR green-based real-time PCR. Antimicrob Agents Chemother (2009) 0.82
Establishment of a surveillance system (utilising Midwifes Data Collection Systems) for monitoring the impact of hepatitis B vaccination on the population prevalence of chronic hepatitis B virus infection in Australia. Aust N Z J Public Health (2008) 0.81
Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is spread internationally by genetically distinct gonococcal populations. J Antimicrob Chemother (2011) 0.80
Estimates of chronic hepatitis B virus infection in the Northern Territory. Commun Dis Intell Q Rep (2005) 0.78
Efficacy and safety of clopidogrel in children with diarrhea associated hemolytic uremic syndrome. Thromb Res (2012) 0.76
Plasmid-mediated resistance of Neisseria gonorrhoeae strains isolated from female sex workers in North Sumatra, Indonesia, 1996. Sex Transm Dis (2003) 0.76
Identification of Australian human respiratory syncytial virus strains containing a 60-nucleotide duplication within the G glycoprotein gene. Pathology (2008) 0.75
Probable transmission of meningococcal disease on a school bus. Med J Aust (2006) 0.75
Refining the public health response to primary meningococcal conjunctivitis. Commun Dis Intell Q Rep (2002) 0.75
Evaluation of the Australian Gonococcal Surveillance Programme. Commun Dis Intell Q Rep (2005) 0.75
Enhanced serological diagnosis of invasive meningococcal disease by determining anti-group C capsule IgM antibody by enzyme immunoassay. Pathology (2005) 0.75
Molecular tests can allow confirmation of invasive meningococcal disease when isolates yield atypical maltose, glucose or gamma-glutamyl peptidase test results. Pathology (2005) 0.75